Silence Therapeutics presents late-breaking Phase II data at AHA
Biotechnology company Silence Therapeutics has shared end-of-treatment data from its Phase II ALPACAR-360 study of short interfering RNA (siRNA) zerlasiran in atherosclerotic cardiovascular disease (ASCVD) patients with high lipoprotein levels.
These data were presented during the Late-Breaking Science Session of the American Heart Association (AHA) Scientific Sessions 2024 in Chicago, Illinois, and simultaneously published in the Journal of the American Medical Association (JAMA).
The results showed that zerlasiran (300mg every 16 weeks, 300mg every 24 weeks or 450mg every 24 weeks) produced greater than 80% mean time-averaged placebo-adjusted reductions from baseline in Lp(a) concentrations over 36 weeks.
This is the first study to report time-averaged Lp(a) analyses, which more accurately evaluates the effects of treatment over time, including intervals between doses.
Maximum Lp(a) reductions exceeded 90%. At the final visit, 60 weeks following initial drug administration, reductions in Lp(a) persisted and no safety concerns emerged with infrequent dosing.
“These data provide additional information to select the best dose and dosing interval for future zerlasiran Phase III trials,” said Steven Nissen, Chief Academic Officer of the Heart, Vascular and Thoracic Institute at Cleveland Clinic and the study’s lead author. “Elevated Lp(a) impacts at least 20% of the global population and is a major cause for morbidity and mortality globally. This is a genetic risk factor that we’ve been unable to treat and I’m excited about the potential for gene-silencing approaches to help these patients.”
Lp(a) is genetically determined and a presumed independent risk factor for cardiovascular disease (CVD). Although an agreed-upon threshold for high Lp(a) is not firmly established, approximately 20% of adults have Lp(a) >125nmol/L (or approximately 50mg/dL).
Evidence has emerged from pathophysiological, epidemiologic, and genetic studies on the potential role of high Lp(a) in contributing to myocardial infarction, stroke, and peripheral arterial disease.
Diana Spencer, Senior Digital Content Editor, DDW
